Bausch Health Companies Inc. Stock
$6.31
2.62%
day before yesterday
NYSE,
Jul 18, 10:10 pm CET
Bausch Health Companies Inc. Stock price
$6.31
+0.13
2.10%
1M
-1.13
15.19%
6M
-1.75
21.71%
YTD
-1.07
14.50%
1Y
-2.33
26.97%
3Y
-11.53
64.63%
5Y
-233.57
97.37%
10Y
-8.04
56.02%
20Y
NYSE,
Closing price Fri, Jul 18 2025
-0.17
2.62%
Powered by
ISIN
CA0717341071
Symbol
BHC
Index
Sector
Industry
Key metrics
Basic
Market capitalization
$2.4b
Enterprise Value
$22.8b
Net debt
$20.4b
Cash
$1.1b
Shares outstanding
369.5m
Valuation (TTM | estimate)
P/E
negative | 1.4
P/S
0.2 | 0.2
EV/Sales
2.3 | 2.3
EV/FCF
18.7
P/B
negative
Financial Health
Equity Ratio
-4.8%
Return on Equity
3.6%
ROCE
8.4%
ROIC
-3.2%
Debt/Equity
-18.2
Show more
Is Bausch Health Companies Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.
Bausch Health Companies Inc. Stock Analysis
Unlock Scores for Free
Analyst Opinions
9 Analysts have issued a Bausch Health Companies Inc. forecast:
Analyst Opinions
9 Analysts have issued a Bausch Health Companies Inc. forecast:
Hold
56%
Sell
44%
Financial data from Bausch Health Companies Inc.
| Mar '25 |
+/-
%
|
||
| Revenue | 9,731 9,731 |
9%
9%
|
|
| Gross Profit | 6,888 6,888 |
8%
8%
|
|
| EBITDA | 2,911 2,911 |
6%
6%
|
EBIT (Operating Income) EBIT | 1,852 1,852 |
11%
11%
|
| Net Profit | -40 -40 |
91%
91%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Bausch Health Companies Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bausch Health Companies Inc. Stock News
Neutral
Accesswire
●
10 days ago
This press release updates the headline of the previously posted release LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to benefici...
Neutral
Accesswire
●
10 days ago
LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Steven Lee as Senior Vice President, Controller and Chief Accounting Officer, effective Monday, July 14. Steven brings extensive experience in financial transformation, mergers and acquisitions, and operational execution.
Neutral
Accesswire
●
11 days ago
LAVAL, QC / ACCESS Newswire / July 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to beneficiaries of the public drug plans of Ontario and Nova Scotia as well as throu...
Company Profile
Manufactures and markets pharmaceutical products
| Head office | Canada |
| CEO | Thomas Appio |
| Employees | 20,700 |
| Founded | 1994 |
| Website | www.bauschhealth.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
